ProCE Banner Activity

Expert Guidance Frequently Asked Questions About CAR T-Cell Therapy in the Community Setting

Text Module
Read expert answers to key questions asked by community practitioners during a live meeting series focused on optimizing CAR T-cell therapy.

Released: February 25, 2020

Expiration: December 19, 2022

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Jae H. Park

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Joshua Sasine

Joshua Sasine, MD, PhD

Assistant Professor of Medicine
Co-Director,
CAR T Program
Division of Hematology and Cellular Therapy
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Gilead Sciences, Inc.

Kite A GILEAD Company

Target Audience

This program is intended for hematologists/oncologists, advanced practice registered nurses, nurses, pharmacists, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recall the scientific principles underlying the use of CAR T-cells
  • Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes
  • Determine best practices for timely referral and having proper channels of communication between community and academic centers to streamline the logistics of delivering therapy
  • Apply multidisciplinary interventions to identify and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy

Faculty Disclosure

Primary Author

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received honoraria from Agios, Celgene, Gilead Sciences/Kite, OptumHealth, Pharmacyclics, and Sanofi; has served on speaker bureaus for Agios, Celgene, Gilead Sciences/Kite, Pharmacyclics, and Sanofi; and has received consulting fees from CRISPR Therapeutics, Gilead Sciences/Kite, Juno, Novartis, and OptumHealth.

Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Jae H. Park, MD, has disclosed that he has received consulting fees from Allogene, Amgen, AstraZeneca, Autolus, GlaxoSmithKline, Incyte, Kite, Novartis, and Takeda.

Joshua Sasine, MD, PhD

Assistant Professor of Medicine
Co-Director,
CAR T Program
Division of Hematology and Cellular Therapy
Cedars-Sinai Medical Center
Los Angeles, California

Joshua P. Sasine, MD, PhD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Lillian McVey,

Editorial Contributor

Lillian McVey has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Ryan P. Topping, PhD

Associate Managing Editor

Additional Information

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 25, 2020, through December 19, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least % and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence and performance in applying evolving clinical evidence and expert guidance to best use CAR T-cells in the treatment of lymphomas and leukemias.